Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart Bio priced IPO at $18 per share, raising $382.5M; Nasdaq debut Thursday (ticker BRVE). The cardiac biotech, founded 2024, develops BHB-1893—a myosin inhibitor licensed from Hengrui Pharma—competing against Camzyos; it's the 17th drugmaker IPO in 2026.